Eli Lilly (LLY) Asset Writedowns and Impairment (2011 - 2012)
Eli Lilly (LLY) posted Asset Writedowns and Impairment of $221.0 million for Q4 2012, down 26.94% quarter-over-quarter from $302.5 million in Q4 2011, and down 26.94% year-on-year from $302.5 million in Q1 2012.
Eli Lilly (LLY) Asset Writedowns and Impairment (2011 - 2012) Analysis & Trends
Eli Lilly (LLY) has reported Asset Writedowns and Impairment for 2 consecutive years, with $221.0 million the latest figure, recorded in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 221.00 Mn |
| Dec 31, 2012 | 221.00 Mn |
| Dec 31, 2011 | 302.50 Mn |
| Dec 31, 2011 | 302.50 Mn |